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Abstract
Background: Diabetes mellitus is associated with alterations in peripheral striated muscles and cardiomyopathy. We
examined diaphragmatic function and fiber composition and identified the role of peroxisome proliferator-activated
receptors (PPAR a and b/d) as a factor involved in diaphragm muscle plasticity in response to type I diabetes.
Methodology/Principal Findings: Streptozotocin-treated rats were studied after 8 weeks and compared with their controls.
Diaphragmatic strips were stimulated in vitro and mechanical and energetic variables were measured, cross bridge kinetics
assessed, and the effects of fatigue and hypoxia evaluated. Morphometry, myosin heavy chain isoforms, PPAR a and b/d
gene and protein expression were also assessed. Diabetes induced a decrease in maximum velocity of shortening (214%,
P,0.05) associated with a decrease in myosin ATPase activity (249%, P,0.05), and an increase in force (+20%, P,0.05)
associated with an increase in the number of cross bridges (+14%, P,0.05). These modifications were in agreement with a
shift towards slow myosin heavy chain fibers and were associated with an upregulation of PPARb/d (+314% increase in gene
and +190% increase in protein expression, P,0.05). In addition, greater resistances to fatigue and hypoxia were observed in
diabetic rats.
Conclusions/Significance: Type I diabetes induced complex mechanical and energetic changes in the rat diaphragm and
was associated with an up-regulation of PPARb/d that could improve resistance to fatigue and hypoxia and favour the shift
towards slow myosin heavy chain isoforms.
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Introduction
Diabetes mellitus may impair respiratory function by reducing
vital capacity, peak trans-diaphragmatic pressures, maximum
voluntary ventilation, and respiratory muscle endurance in
humans [1,2]. However the precise mechanisms of these changes
remain a matter of debate since several mechanisms related to
diabetes neuropathy and/or myopathy may be involved in
respiratory function impairment [3]. Moreover, peripheral airway
involvement cannot be excluded [3] which, in association with
complex changes in neuroventilatory drive and perception of
dyspnea [4], may preclude a precise analysis of respiratory muscle
function in vivo. The duration of diabetes and the indirect role of its
major complications may also markedly interfere with these
changes and these important points have been rarely taken into
account. A number of biochemical enzymatic and functional
changes in skeletal muscles, including respiratory muscles, have
been reported in diabetes mellitus including altered carbohydrate
and lipid metabolism [5–7], oxidative stress [8], and changes in
membrane electrophysiology [9]. Van Lunteren et al. [10] recently
reported an increased expression in genes involved in lipid
metabolism, oxidative stress, and protein ubiquitination associated
with a decreased expression in gene involved in carbohydrate
metabolism. However, few studies have directly assessed the
intrinsic properties of diaphragmatic muscle in diabetes mellitus
[11] and some of them are difficult to interpret since they followed
only a very short exposure to diabetes [8].
We examined diaphragmatic functional modifications induced
by diabetes in the rat, including mechanics, energetics, and cross-
bridges kinetics, under baseline condition and during fatigue and
hypoxia, using the well-known model of streptozotocin-induced
type I diabetes. Diaphragm histological structure and myosin
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members of the nuclear hormone receptor superfamily, namely
peroxisome proliferator-activated receptor (PPAR) have critical
role in lipid and glucose metabolism and homeostasis, skeletal
muscle fiber type expression and endurance [12], and in diabetic
myocardium remodelling [13,14], we hypothesized that changes in
PPAR expression contribute to functional and structural changes
in diabetic diaphragm. We focussed on PPAR a and b/d the main
isotypes expressed in the rat diaphragm [15]. Diaphragm
histological structure and myosin heavy chain (MHC) composition
were also analysed.
In summary, our data suggest that up-regulation of PPARb/d is
associated with functional and structural changes induced by type
I diabetes in the diaphragm.
Methods
Care of the animals conformed to the officials edict presented
by the French Ministry of Agriculture (Paris, France) and the
recommendations of the Helsinki Declaration. Thus, these
experiments were conducted in authorized laboratories (UMRS
INSERM 956, UMR CNRS 7215, UMRS INSERM 974) and
under the supervision of authorized researchers (permit
numbers 75–636 and 75–786). Rats were maintained on a
12:12-h light dark photoperiod and received rat chow and water
ad libitum.
Animals
Six-week old male Wistar rats (body weight 21265 g, Charles
River Laboratories, France) were assigned either to control group
(n=12) and diabetic group (8 weeks after streptozotocin adminis-
tration, n=12). Diabetes was induced by intravenous injection of
streptozotocin (65 mg/kg; Sigma Chemical, l’Isle Abeau Chesnes,
France) in the femoral vein [16,17]. Transcutaneous determination
of glucose blood concentration (GlucotrendH; Boehringer, Man-
heim, Germany) was performed to ensure that the animals became
diabetic (i.e., glucose blood concentration .25 mM/l). At the
moment of euthanasia, blood samples were withdrawn and
centrifuged at 5,000 g for 15 min; then plasma fractions were
collected and stored at 220uC for further determination of non-
fasting glucose blood concentrations (Cobas Integra 400; Roche
Diagnostic, Manheim, Germany).
Mechanical and energetic parameters
After a brief anesthesia with thiopental, a muscle strip from the
ventral costal diaphragm was dissected from the muscle in situ.
This diaphragm strip was immediately vertically suspended in a
200 ml jacketed reservoir with Krebs-Henseleit bicarbonate buffer
solution (NaCl 118 mM, KCl 4.5 mM, MgSO4 1.2mM, KH2PO4
1.1mM, NaHCO3 25mM, CaCl2 2.5mM and glucose 4.5 mM)
prepared daily with highly purified water. The bathing solution
was bubbled with 95% oxygen and 5% carbon dioxide, resulting
in a pH 7.40 and maintained at 29uC.
Preparations were field-stimulated (30 V) by using two platinum
electrodes with rectangular-wave pulses of 1 ms duration at
10 pulses/min in the twitch mode. After a 30 min stabilization
period, at the apex of the length-active isometric force curve
(Lmax), diaphragm muscle strips recovered their optimal mechan-
ical performance [18,19]. Measurements of mechanical variables
were made at Lmax under tetanic stimulation at 50 Hz (10 trains
each minute of 300 ms duration, 1 ms rectangular pulses) to
obtain maximal contractions. Cross-sectional area was calculated
from the ratio of muscle weight to muscle length, assuming a
muscle density of 1.06.
The electromagnetic lever system has been described previously
[20]. All the analyses were made from digital records of force and
length obtained using specific software, as previously described
[20,21]. Contraction variables including the maximum shortening
velocity (Vmax), the extent of shortening (DL), peaks of the positive
derivative normalized to cross-sectional area (+dF/dt) and the
active force normalized to cross-sectional area (AF) were
measured. Variables characterizing relaxation including the
maximum lengthening velocity (Vrmax) and peak of the negative
derivative normalized per cross-sectional area (-dF/dt
21) were also
determined (Figure 1). Mechanical variables were calculated from
3 consecutive tetanic contractions preloaded at Lmax with
increasing afterload from zero load to fully isometric contraction.
The first contraction was abruptly clamped to zero load just after
the electrical stimulus, with critical damping in order to slow the
first and rapid shortening overshoot resulting from the recoil of
series passive elastic components, enabling determination of Vmax.
The second contraction was isotonic and loaded with preload only.
DL and Vrmax were determined from this contraction. The last
contraction was fully isometric at Lmax. AF, +dF/dt and –dF/dt
were determined from this fully isometric contraction (Figure 1).
The force-velocity curve was derived from the peak shortening
velocity plotted against the total force (resting force + active force)
normalized per cross-sectional area [22]. Both measurements were
obtained from 10 tetanic contractions, from zero load to fully
isometric contraction. The total force-velocity curve was fitted
according to the Hill equation [23]. The following energetic
parameters were derived from the Hill hyperbola: the curvature of
the hyperbola (G), non-normalized maximum power output
(Emax), and maximum mechanical efficiency (Effmax) [22]. The
following variables of cross-bridges kinetics were determined from
mechanical data with the equations of A.F. Huxley [24]: the total
number of cross-bridges per mm
2 (m), elementary force per cross-
bridge (P) and myosin ATPase activity (kcat).
Effect of fatigue
After determination of baseline values, fatigue was induced by
repeatedly stimulating the diaphragmatic strip with 75 trains.min
21
of 300 ms duration at stimulation frequency of 50 Hz. Stimulation
continued until the muscle strip was fatigued to a point where it
generated 45–50% of its original tetanic tension measured before
the fatigue procedure. Mechanical variables were recorded just
after completion of the fatigue procedure and after 20 min of
recovery.
Effect of hypoxia
Hypoxia was induced by switching the bubbling gas from 95%
oxygen-5% carbon dioxide to 95% nitrogen-5% carbon dioxide
leading to a fall in PO2 from 453663 to 54613 mmHg.
Mechanical properties of the diaphragmatic strips were measured
every 5 min over 15 min. Recovery from hypoxia was obtained by
switching back to 95% oxygen-5% carbon dioxide and measure-
ments were performed every 5 min over 15 min.
Morphometry
Diaphragm cryosections (5 mm-width) were fixed in 4%
paraformaldehyde and were incubated with mouse monoclonal
anti-a actinin antibody (1/200, Sigma). Sections were revealed by
anti-mouse IgG Alexa Fluor 488 (1/250, Molecular Probes,
Eugene, OR) and mounted in Vectashield medium with Dapi
(Vector Laboratories, Paris, France). Fluorescence was visualized
using a DMRBE Leica microscope equipped with a 40x-oil
epifluorescence objective. Sections exposed only to secondary
PPAR in Diabetic Diaphragm
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background staining.
MHC isoform compositions
MHC isoform composition was determined in purified myosin
as previously described [25]. In brief, sodium dodecyl sulfate-
polyacrylamide (SDS-PAGE) minigel electrophoresis was per-
formed in a mini-Protean II Dual slab cell system (Bio-Rad,
Marnes-la-Coquette, France). MHC isoforms were separated on
8% polyacrylamide gels containing 30% glycerol for 24 h at 4u C
and 70 V. Gels were stained with Coomassie blue. Myosin
isoforms were quantified using Image Gauge software (Fujifilm,
Tokyo, Japan).
Extraction of proteins and quantification of PPARa and
PPARb/d by Western blots
A nuclear-enriched protein fraction was extracted from frozen
diaphragm fragments using a commercial kit (NE-PER nuclear
and cytoplasmic extraction reagents, Pierce). Protein concentra-
tions were determined using NanoDropH (ND-1000 spectropho-
tometer, NanoDrop Products, Wilmington, DE). Samples were
stored at 280uC until use. Protein samples were subjected to SDS-
polyacrylamide gel electrophoresis (PAGE), transferred to nitro-
cellulose membranes and blotted with polyclonal anti-PPARa (1/
250, SC 1985, Santa Cruz Biotechnologies, Santa Cruz, CA) and
anti- PPARb/d (1/250, SC 1987, Santa Cruz Biotechnologies).
The secondary antibody was anti-goat horseradish peroxidase (1/
5000). Membranes were visualized with enhanced chemilumines-
cent kit (ECL, Amersham, Pantin, France). Light emission was
detected with a camera (Laser 3000, Fujifilm) and quantified using
Image Gauge software (Fujifilm). The S-Ponceau staining was used
to verify that equal amounts of protein were loaded. Quantifica-
tion of protein was normalized to actin.
Absolute quantitative real-time PCR analysis
Total RNA was isolated from diaphragm samples using
Qiagen RNeasy Kits (Qiagen France, Courtaboeuf, France)
according to the manufacter’s instructions. Further purification
of RNA samples to remove genomic DNA was carried out with
DNAse I (Roche Diagnostics, Meylan, France). The quantity of
mRNA isolated from each sample was determined using the
adsorption of each solution at 260 and 280 nm (ND-1000
spectrophotometer). The purity of each sample was estimated
using the A260/A280 ratio and the quality checked using
denatured agarose gel electrophoresis. Isolated total RNA was
stored in aqueous solution at 280uC. Reverse transcription was
performed on 500 ng total RNA using the SuperSript III
Reverse Transcriptase (Invitrogen, Mantes La Jolie, France).
Standards were generated by PCR using cDNA sub-cloned into
pGEM-T-easy (Kit A1380, Promega France, Charbonie `res-Les-
Figure 1. Typical traces of shortening (L/Lmax) and force (F) obtained in a control and a diabetic rat. Three consecutive tetanic (50 Hz)
contractions preloaded at Lmax with increasing afterload from zero load to fully isometric contraction are shown: 1) the first contraction was abruptly
clamped to zero load, enabling determination of maximum shortening velocity (Vmax); 2) the second contraction was isotonic and loaded with
preload only, enabling determination of extent of shortening (DL) and maximum lengthening velocity (Vrmax); 3) the third contraction was fully
isometric at Lmax, enabling determination of active force (AF), and peaks of the positive (+dF/dt
21) and negative (2dF/dt
21) derivative normalized to
cross-sectional area.
doi:10.1371/journal.pone.0011494.g001
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Specific primers for cDNAs were chosen according to the
sequences available in Genbank. The sequences for PPARa
were: forward, AACATCGAGTGTCGAATATGTGG and
reverse, AGCCGAATAGTTCGCCGAAAG. The sequences
for PPARb/d were: forward TTGAGCCCAAGTTCGAG-
TTTG and reverse, CGGTCTCCACACAGAATGATG. Re-
al-time PCR was performed using a LightCycler (Roche
Diagnostics). All real time PCR quantification were performed
simultaneously with linearized plasmid standards (from 10
23 to
10
26 ng/ml) and a negative water control. The concentrations
of PPARa and PPARb/d in the tissues were interpolated
from standard curves, actin was used as a reference gene for
comparative analysis.
Statistical analysis
Data are expressed as means 6 SEM. Comparisons between
groups were performed using the Student’s t test. All P values were
two-tailed and a value of P,0.05 was considered significant.
Statistical analysis was performed using NCSS 6.0 software
(Statistical Solutions Ltd., Cork, Ireland).
Results
Body weight at 8 weeks was significantly lower in diabetic
compared to control rats (27469 g vs. 33766g ,P ,0.05). Blood
glucose concentrations was significantly higher in diabetic rats
compared to control rats (41.161.2 vs.10.460.2 mM; P,0.05).
There was no significant difference in Lmax values between groups
(10.460.4 vs. 9.660.2 mm, NS).
Mechanical and energetic properties
Baseline values of mechanical and energetic parameters and
cross-bridges kinetics are shown in Table 1. In diabetic rats, we
observed a significant decrease in DL( 229%, P,0.05), Vmax
(214%, P,0.05) and Vrmax (245%, P,0.05) and a significant
increase in AF (+20%, P,0.05) and +dF/dt (+41%, P,0.05). The
opposite effects on force and velocity were responsible for no
significant difference in the peak power output (219%, NS) and
the curvature of the force-velocity curve (-14%, NS) (Figure 2).
The number of cross-bridges (m) was significantly increased
(+14%, P,0.05) in diabetic rats but the force per cross-bridge
remained unchanged (Table 1).
Figure 2. Total force (TF)-velocity (V) curves in control (n=12) and diabetic (n=12) diaphragms. Panel A: absolute values were used to
determine the peak power output (Emax). Panel B: the normalized TF and V values were used to determine the normalized peak power output and the
curvature (G) of the F-V curve. Diabetic diaphragms were characterized by a significant increase in maximum TF (TFmax) and a significant decrease in
maximum shortening velocity (Vmax) which resulted in non significant (NS) changes in Emax and G.
doi:10.1371/journal.pone.0011494.g002
Table 1. Baseline main mechanical, energetic and cross-
bridges kinetic variables.
Control (n=12) Diabetes (n=12)
MECHANICS
DL( % L max)4 1 612 9 61*
Vmax (Lmax.s
21)6 . 9 60.2 5.960.2*
AF (mN.mm
22)8 1 629 7 61*
+dF/dt (mN.mm
22.s
21) 18626199 26316192*
Vrmax (Lmax.s
21) 29.560.4 25.260.4*
2dF/dt (mN.mm
22.s
21) 217846183 219126119
ENERGETICS
G3 . 5 60.2 4.160.4
Emax(mN.mm
22.s
21)4 4 633 6 62
Effmax (%) 40624 4 63
CROSS-BRIDGE KINETICS
m( 1 0
9.mm
22) 10.160.4 11.560.3*
p (pN) 8.160.1 8.560.2
kcat (s
21) 10.961.3 6.661.0*
DL= maximum extent of shortening; Vmax= maximal unloaded shortening
velocity; AF= isometric active force normalized per cross sectional area (CSA);
+dF/dt= peak of positive force derivative normalized per CSA; Vrmax=
maximum lengthening velocity; 2dF/dt= peak of negative force derivative
normalized per CSA; G= curvature of the hyperbola; Emax= non-normalized
maximum power output; Effmax= maximum mechanical efficiency; m= total
number of cross-bridges per mm
2; p= elementary force developed per cross-
bridge; kcat= myosin ATPase activity. Values are expressed as mean 6 SEM.
* P,0.05 versus control.
doi:10.1371/journal.pone.0011494.t001
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Following the fatigue protocol, an equivalent value of AF was
reached in each group but the decrease in Vmax was less
pronounced in diabetic diaphragms. Conversely, the recovery
from fatigue was better in diabetic than in controls (Figure 3).
Hypoxia
In controls, hypoxia induceda severedecrease inAF(288%) and
a less severe decrease in Vmax (228%). Diaphragms from diabetic
rats were more resistant to hypoxia and a more rapid recovery from
hypoxia was observed compared to controls (Figure 4).
Figure 3. Evolution of main mechanical variables during fatigue and early recovery phase of fatigue in control (n=12) and diabetic
(n=12) rats. Panel A: AF= isometric active force normalized per cross sectional area (CSA). Panel B: Vmax= maximum shortening velocity. Values are
expressed as mean percent of baseline 6 SEM. *: P,0.05 versus Control.
doi:10.1371/journal.pone.0011494.g003
Figure 4. Evolution of main mechanical variables during hypoxia and recovery from hypoxia in control (n=12) and diabetic (n=12)
rats. Panel A: AF= isometric active force normalized per cross sectional area (CSA). Panel B: Vmax= maximum shortening velocity. Values are
expressed as mean percent of baseline 6 SEM. *: P,0.05 versus Control.
doi:10.1371/journal.pone.0011494.g004
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Morphometric analysis, performed with a-actinin antibody,
showed regular striation patterns in both control and diabetic rat
diaphragm and did not reveal any structural abnormalities (Figure 5).
Four MHC isoforms were detected in the control rat
diaphragm, the proportion of slow MHC-I type and overall fast
MHCs isoforms being respectively <30% and <70% (Figure 6).
Compared with controls, diabetic diaphragm contained a greater
proportion of slow MHC fibers associated with a significant
decrease in IIA and IIB MHC fibers and an unchanged
proportion of IIX MHC fibers (Figure 6).
PPAR gene and protein expression
Compared to control, PPARb/d transcripts were significantly
increased (+314%, P,0.05) in diabetic diaphragm. In contrast, the
PPARa mRNA level showed no significant change compared with
healthy diaphragms (Figure 7). Consistent with mRNA expression,
wefoundthatdiabeteswasassociated withanincreaseintheprotein
expression of PPARb/d compared to controls (+190%, P,0.05).
The protein expression of PPARa in diaphragm from diabetic rats
did not significantly differ to that reported in controls (Figure 7).
Discussion
We observed that type I diabetes induces marked changes in the
rat diaphragm, mainly as a decrease in velocity of shortening
associated with an increase in force, without significant change in
peak power output. The analysis of cross-bridge kinetics showed a
significant increase in the number of cross bridges associated with
a decreased in myosin ATPase activity. These modifications were
in agreement with a shift towards slow MHC fibers which were
associated with an increase in PPARb/d. Together these
modifications provided a greater resistance to fatigue and hypoxia
with faster recovery in the diaphragm of diabetic rats.
There are some controversies concerning respiratory function in
diabetes mellitus. Reduced vital capacity, peak trans-diaphrag-
matic pressures, maximum voluntary ventilation, and respiratory
muscle endurance have been reported in diabetic patients [1,2].
However, the mechanism of these changes remains a matter of
debate because of the adverse effects of diabetes on peripheral
airway, nerve conduction, neuroventilatory drive and perception
of dyspnea [3,4,26], which precludes a precise analysis of
respiratory muscle function in vivo. Streptozotocin-induced diabe-
tes in the rat has been widely used as an animal model of diabetes
mellitus [5–10,16,17] but few studies investigated the intrinsic
diaphragmatic mechanical properties. McGuire et al. [11] studied
the rat diaphragm after 2 months of diabetes. Although twitch
tension and action potential were not modified, they reported a
slight (213%) but significant decrease in tetanic tension associated
with a greater degree of fatigue, and highlighted noticeable
differences between diaphragm and other skeletal muscles [27].
Compared with our study, the only experimental differences were
the use of isometric twitch contraction during the whole
procedure. Hida et al. [8] also observed a significant decrease in
diaphragmatic contractility in diabetic rats which could be
reversed by treatment with N-acetylcysteine but this study is
difficult to interpret since only a very short period of diabetes (3
and 7 days) was induced. In contrast to these studies, we observed
that, although velocity of shortening was slightly decreased, force
was increased, without significant change in peak power output.
Moreover, our results concerning mechanics, energetics, fatigue,
MHC composition, and PPAR isotypes, are consistent overall.
Figure 5. Morphometric study of diaphragm in control and
diabetic rats (bar=10 mm). Longitudinal sections are stained with a-
actin antibody. Nuclei stained with Dapi appear in blue. No significant
change was observed between groups.
doi:10.1371/journal.pone.0011494.g005
Figure 6. Diaphragmatic myosin heavy chain (MHC) composi-
tion in control (n=6) and diabetic (n=6) rats. Data are expressed
as mean 6 SEM. *: P,0.05 versus Control.
doi:10.1371/journal.pone.0011494.g006
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contains approximately 40% of slow type I fibers, 27% of type IIA,
and 33% of rapid type IIB fibers [28]. The shift toward slow MHC
fibers reported here (Figure 6) is consistent with the observed
decrease in shortening velocity and myosin ATPase activity
(Table 1). It is widely accepted that the expression of MHC
isoforms correlates with shortening velocity and myosin ATPase
activity, the MHCslow isoform displaying the lowest shortening
Figure 7. PPARa and b/d mRNA and protein expression in diaphragm from Control (n=6) and diabetic (n=6) rats. *: P,0.05 versus
Control. Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0011494.g007
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expressing MHCslow generated less maximum specific forces than
fibers expressing MHCIIX or MHCIIA although their calcium
sensitivity is considered to be higher [29]. Therefore, this fast-to-
slow fiber shift reported in our study was also associated with an
increase in force and the number of cross-bridges (Table 1),
explaining why the peak power output and the curvature of the
force-velocity curve remained unchanged (Figure 2). The lack of
change in force per cross-bridge we observed (Table 1) is due to
the fact that the unitary force per cross-bridge is similar across
MHC isoforms and that differences in specific forces reflect
differences in MHC content per sarcomere [29]. The relative
increased proportion of fibers expressing the MHCslow isoform
may explain the greater fatigue resistance of diabetic diaphragm
[30]. It has been shown that fatigue-resistant fibers comprise those
expressing the MHCslow and MHCIIA isoforms and that they are
characterized both by a low myosin ATPase activities and a high
succinate dehydrogenase activity which reflects the overall aerobic
capacity of muscle fibers [31]. The fast-to-slow fiber shift may also
explain the greater hypoxia resistance of diabetic diaphragm since
it has also been shown that slow fibers are also less sensitive to
hypoxia [32]. Nevertheless, we cannot ruled out the hypothesis
that other associated mechanisms were involved particularly
because modifications inducing resistance to hypoxia may occur
without significant changes in myosin heavy chain isoform [33].
PPARs belong to a family of nuclear receptors that regulate
fatty acid metabolism via ligand-dependent transcriptional activa-
tion of target genes. PPARa mediates lipid-induced activation of
fatty acid b-oxidation and plays a central role in the metabolic and
energetic homeostasis of striated muscles in which it is abundantly
expressed, including the diaphragm [34]. In PPARa knockout
mice, diaphragmatic muscle mechanics, energetics, and cross-
bridge kinetics are markedly impaired, leading to histological
injuries [34]. PPARb/d expression predominates in heart and
skeletal muscle, including the diaphragm [15]. PPARb/d has been
shown to engineer the fast-to-slow fiber shift induced by endurance
training [35]. In our study, we observed an increase in gene and
protein expression of PPARb/d without significant changes for
PPARa. These results are consistent with those of Van Lunteren
et al. [10] who found a global increase in expression of genes
involved in lipid metabolism in the diaphragm of type I diabetic
rats. Since PPARb/d drives the synthesis of type I muscle fibers
[12], it is likely that it played a crucial role in the mechanical and
energetic changes induced by diabetes in the rat diaphragm.
PPARa and PPARb/d direct distinct metabolic regulatory
programs and PPARa mice develop lipotoxic cardiomyopathy
which resembles the diabetic cardiomyopathy whereas PPARb/d
mice do not [36]. In contrast to that we observed in the diabetic
diaphragm, Yu et al. [17] observed a decrease in PPARb/d gene
and protein expression in the myocardium of diabetic rats whereas
Huang et al. [37] observed an increase in PPARb/d gene
expression in the lung. Taken together, these results suggest that
PPARb/d expression in diabetes differs markedly from one tissue
to another [37,38], possibly depending on the balance between the
two major fuel utilization pathways, glucose versus fatty acid and
their cross-talk. Since PPARb/d has been suggested as a potential
target for metabolic modulation therapy aimed at diabetes-
induced cardiomyopathy [36], our study may signal possible
adverse effects related to this differential expression of PPARb/d
in different tissues during diabetes. Interestingly, we did not find
significant changes for PPARa, whereas increased PPARa
expression has been reported in diabetes type II animal models
[39]. Such differences support the hypothesis that early stages of
obesity and insulin resistance are accompanied by increased rather
than reduced b-oxidation [39].
The following points should be considered when assessing the
clinical relevance of our results. First, this in vitro study only dealt
with intrinsic diaphragmatic contractility. Observed changes in
diaphragmatic function in vivo in diabetes depend also on
modifications in diaphragmatic arterial blood flow, central nervous
system respiratory drive and neuromuscular transmission. Second,
this study was lead at 29uC and at low-frequency stimulation.
However, diaphragmatic muscle must be studied at low temper-
ature because stability of mechanical parameters is not sufficient at
37uC, and they must be studied at low-frequency because high-
frequency stimulation induces core hypoxia [40]. The experimen-
tal model used is thought to mostly reflect type I diabetes mellitus
whereas type II diabetes mellitus is usually studied using genetic
models such as Zucker rats [41]. It should also be pointed out that
our study was conducted in animals with uncontrolled diabetes
whereas most diabetic patients receive some form of therapy. The
diabetes-induced changes were significant after 8 weeks of
diabetes. This result is consistent with our previous observation
in the diabetic rat myocardium [16,17], and emphasizes the
importance of the duration of exposure to diabetes in experimental
models and thus to differentiate models mimicking acute
hyperglycemia [8] and those mimicking diabetes [41]. Although
the diaphragmatic function was preserved in our model, the long-
term consequences of at least some of these adjustments may
finally impaired muscle function, for example, if there is increased
mitochondrial biogenesis with concomitant oxidative stress. Lastly,
this study was performed in the rat and species differences cannot
be excluded although MHC quota is quiet similar in rat and
human diaphragms [28,42].
In conclusion, in rat diaphragm, diabetes type I induced
complex mechanical and energetic changes, associated with
improved resistances to fatigue and hypoxic condition that may
be explained mainly by a shift towards slow MHC isoforms
associated with an increased expression of PPARb/d gene and
protein.
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